Blocking autophagy by the two-pore channels antagonist tetrandrine improves sorafenib-induced death of hepatocellular carcinoma cells.

[1]  K. Skelding,et al.  Targeting the two-pore channel 2 in cancer progression and metastasis , 2022, Exploration of targeted anti-tumor therapy.

[2]  K. Chandrashekar,et al.  Autophagy and cancer: Can tetrandrine be a potent anticancer drug in the near future? , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  J. Parrington,et al.  TPC2 targeting evolution: Leveraging therapeutic opportunities for cancer. , 2021, Cell chemical biology.

[4]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics , 2021, Journal of the National Cancer Institute.

[5]  X. Miao,et al.  Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma , 2021, Theranostics.

[6]  Yafei Wu,et al.  Autophagy, an accomplice or antagonist of drug resistance in HCC? , 2021, Cell Death & Disease.

[7]  S. Zahler,et al.  Gene editing and synthetically accessible inhibitors reveal role for TPC2 in HCC cell proliferation and tumor growth. , 2021, Cell chemical biology.

[8]  J. López-González,et al.  The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity , 2020, Frontiers in Oncology.

[9]  S. Smaili,et al.  Effective Synergy of Sorafenib and Nutrient Shortage in Inducing Melanoma Cell Death through Energy Stress , 2020, Cells.

[10]  J. Parrington,et al.  Endolysosomal Ca2+ Signaling in Cancer: The Role of TPC2, From Tumorigenesis to Metastasis , 2019, Front. Cell Dev. Biol..

[11]  A. Tsung,et al.  Autophagy: Dual Response in the Development of Hepatocellular Carcinoma , 2019, Cells.

[12]  Senlin Xu,et al.  Targeting the Ca2+/Calmodulin-dependent protein kinase II by Tetrandrine in human liver cancer cells. , 2019, Biochemical and biophysical research communications.

[13]  Zhi-nan Chen,et al.  Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma , 2018, Cancer medicine.

[14]  J. González‐Gallego,et al.  Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors , 2018, Experimental & Molecular Medicine.

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  Xinyu Bai,et al.  Anticancer activity of tetrandrine by inducing pro‐death apoptosis and autophagy in human gastric cancer cells , 2018, The Journal of pharmacy and pharmacology.

[17]  G. Russo,et al.  Autophagy inducers in cancer , 2018, Biochemical pharmacology.

[18]  Shekoufeh Almasi,et al.  The hidden potential of lysosomal ion channels: A new era of oncogenes. , 2018, Cell calcium.

[19]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[20]  A. Filippini,et al.  Naringenin Impairs Two-Pore Channel 2 Activity And Inhibits VEGF-Induced Angiogenesis , 2017, Scientific Reports.

[21]  Zhe-Sheng Chen,et al.  Autophagy and multidrug resistance in cancer , 2017, Chinese journal of cancer.

[22]  Lei Chen,et al.  New knowledge of the mechanisms of sorafenib resistance in liver cancer , 2017, Acta Pharmacologica Sinica.

[23]  Cheng-Chang Chen,et al.  Two-Pore Channels: Catalyzers of Endolysosomal Transport and Function , 2017, Front. Pharmacol..

[24]  R. Preissner,et al.  Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma , 2017, The Journal of Biological Chemistry.

[25]  A. Vollmar,et al.  Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells. , 2017, Cancer research.

[26]  S. Smaili,et al.  Glutamate induces autophagy via the two-pore channels in neural cells , 2016, Oncotarget.

[27]  Sandip Patel,et al.  Function and dysfunction of two-pore channels , 2015, Science Signaling.

[28]  Y. Sakurai,et al.  Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment , 2015, Science.

[29]  Chang Liu,et al.  Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1 , 2015, Acta Pharmacologica Sinica.

[30]  Chunrong Yu,et al.  Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species , 2015, Cell & Bioscience.

[31]  A. Galione,et al.  VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2–dependent Ca2+ signaling , 2014, Proceedings of the National Academy of Sciences.

[32]  M. Mann,et al.  High susceptibility to fatty liver disease in two-pore channel 2-deficient mice , 2014, Nature Communications.

[33]  G. Churchill,et al.  NAADP-sensitive two-pore channels are present and functional in gastric smooth muscle cells. , 2014, Cell calcium.

[34]  J. Rostas,et al.  Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition. , 2014, Cellular signalling.

[35]  S. Muallem,et al.  Convergent regulation of the lysosomal two‐pore channel‐2 by Mg2+, NAADP, PI(3,5)P2 and multiple protein kinases , 2014, The EMBO journal.

[36]  W. Qiu,et al.  Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells , 2014, Cell Death and Disease.

[37]  Chunrong Yu,et al.  Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling , 2013, British Journal of Cancer.

[38]  S. Sinha,et al.  Role of the Crosstalk between Autophagy and Apoptosis in Cancer , 2013, Journal of oncology.

[39]  Ke Gong,et al.  Autophagy-related Gene 7 (ATG7) and Reactive Oxygen Species/Extracellular Signal-regulated Kinase Regulate Tetrandrine-induced Autophagy in Human Hepatocellular Carcinoma* , 2012, The Journal of Biological Chemistry.

[40]  P. Gomez-Suaga,et al.  LRRK2 as a modulator of lysosomal calcium homeostasis with downstream effects on autophagy , 2012, Autophagy.

[41]  A. Hobisch,et al.  Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways , 2012, Endocrine-related cancer.

[42]  G. Churchill,et al.  Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP , 2011, Human molecular genetics.

[43]  Ke Gong,et al.  Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma , 2011, International journal of cancer.

[44]  G. Churchill,et al.  Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Regulates Autophagy in Cultured Astrocytes* , 2011, The Journal of Biological Chemistry.

[45]  R. Oostendorp,et al.  Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 , 2011, Leukemia.

[46]  Taufiq Rahman,et al.  An NAADP-gated Two-pore Channel Targeted to the Plasma Membrane Uncouples Triggering from Amplifying Ca2+ Signals , 2010, The Journal of Biological Chemistry.

[47]  A. Galione,et al.  Purified TPC Isoforms Form NAADP Receptors with Distinct Roles for Ca2+ Signaling and Endolysosomal Trafficking , 2010, Current Biology.

[48]  N. Dun,et al.  Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling , 2009, The Journal of cell biology.

[49]  O. Griesbeck,et al.  The two-pore channel TPCN2 mediates NAADP-dependent Ca2+-release from lysosomal stores , 2009, Pflügers Archiv - European Journal of Physiology.

[50]  A. Galione,et al.  The acid test: the discovery of two-pore channels (TPCs) as NAADP-gated endolysosomal Ca2+ release channels , 2009, Pflügers Archiv - European Journal of Physiology.

[51]  A. Galione,et al.  NAADP mobilizes calcium from acidic organelles through two-pore channels , 2009, Nature.

[52]  Alexander M. Lewis,et al.  Identification of a chemical probe for NAADP by virtual screening , 2009, Nature chemical biology.

[53]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[54]  Jorge A. Almenara,et al.  The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. , 2007, Cancer research.

[55]  P. Dent,et al.  The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress , 2007, Molecular and Cellular Biology.

[56]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[57]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.

[58]  Yu-Jen Chen.  Potential role of tetrandrine in cancer therapy. , 2002, Acta pharmacologica Sinica.

[59]  A. Galione,et al.  Coordination of Ca2+ signalling by NAADP. , 2001, Trends in biochemical sciences.

[60]  J. Luzio,et al.  The Role of Intraorganellar Ca2+In Late Endosome–Lysosome Heterotypic Fusion and in the Reformation of Lysosomes from Hybrid Organelles , 2000, The Journal of cell biology.

[61]  J R Lemos,et al.  Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+)-activated K+ channels. , 1994, Life sciences.

[62]  Q.-Y. Liu,et al.  Tetrandrine: A novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells , 1991, Neuropharmacology.